Pharmaceutical Industry 27 Apr – 3 May: Ft MSK, Merck, Roche, Gilead, Arcus and Ray Therapeutics
- MSK researchers have reported encouraging long-term follow-up results from a small phase 1 trial of a personalised mRNA vaccine for pancreatic cancer.
- Elsewhere in pharma, Merck has announced a major $1 billion Google Cloud AI partnership, gained FDA approval for a new HIV therapy, while Roche, Gilead, Arcus and Ray Therapeutics have all reported important pipeline developments.
A New Signal of Hope in Pancreatic Cancer
An experimental personalised mRNA cancer vaccine being studied by Memorial Sloan Kettering Cancer Center, BioNTech and Genentech is continuing to show promise in one of oncology’s hardest territories: pancreatic cancer.
Follow-up findings from a small phase 1 clinical trial suggest that the vaccine, autogene cevumeran, may be capable of triggering a meaningful and long-lasting immune response in some patients.
The results are especially striking because pancreatic cancer remains one of the deadliest forms of cancer, with a five-year survival rate of around 13%, according to the American Cancer Society’s Cancer Statistics 2026 report.
The latest data, presented by Dr Vinod Balachandran at the 2026 Annual Meeting of the American Association for Cancer Research, showed that nearly 90% of patients whose immune systems responded to the vaccine were still alive up to six years after receiving their last treatment.
For a disease where progress has often been frustratingly slow, the results offer a serious reason for cautious optimism.
How the Personalised mRNA Vaccine Works
The vaccine being studied is not designed to prevent cancer in the way a flu vaccine prevents infection. Instead, it is a therapeutic cancer vaccine, meaning it is intended to train the body’s immune system to recognise, attack and potentially control cancer after it has already developed.
In the phase 1 trial, 16 patients received the autogene cevumeran vaccine after pancreatic cancer surgery. The treatment was given alongside chemotherapy and an immunotherapy drug known as a checkpoint inhibitor.
Each vaccine was custom-made for the individual patient. After surgery, the patient’s tumour was genetically analysed to identify unique mutations in the tumour DNA. Scientists then used this information to design a personalised vaccine intended to teach the immune system to recognise those tumour-specific features as foreign.
In simple terms, the vaccine attempted to show the immune system what made each patient’s cancer different from healthy tissue, giving the body a clearer target to attack.
The Results That Are Drawing Attention
Of the 16 patients in the study, 8 developed a vaccine-driven immune response. In those patients, the vaccine activated tumour-specific immune cells, including T cells capable of targeting cancer cells.
Among the 8 patients whose immune systems responded, 7 were still alive 4 to 6 years after surgery. That represents 87.5% of the responder group.
By contrast, among the 8 patients who did not respond to the vaccine, only 2 were still alive, with a median survival time of 3.4 years.
The findings remain early and come from a small patient group, but they point to a potentially important biological signal: when the vaccine successfully activates the immune system, some patients appear to do well for years after treatment.
Why T Cells Matter So Much
A crucial part of the MSK research involved detecting and tracking the immune system’s T cells after vaccination. This work was led by computational biologist Benjamin Greenbaum, PhD, Co-Director of the Olayan Center for Cancer Vaccines.
Researchers found that patients who responded to the personalised mRNA vaccine developed CD8+ T cells, which are cancer-killing immune cells. These cells lasted for up to six years and showed no signs of slowing down.
The researchers also found that responding patients produced CD4+ T cells, another important class of immune cells. Scientists believe that effective cancer vaccines may need both: CD8+ T cells to directly attack cancer cells, and CD4+ T cells to help strengthen and sustain the wider immune response.
This long-lasting immune activity is one of the most important aspects of the study. Rather than giving the immune system a short-lived boost, the aim is to train it to recognise and fight cancer over the long term.
The Human Story Behind the Trial
Behind the scientific data is the story of patients such as Donna Gustafson, the first person to enrol in the autogene cevumeran trial in late 2019.
Donna was diagnosed with pancreatic cancer at the age of 66 while visiting one of her three daughters in Australia with her husband, Ed. After returning to the United States, she came to MSK for treatment.
She met surgeon Jeffrey Drebin, MD, PhD, and later worked with Dr Balachandran and medical oncologist Eileen O’Reilly, MD. The team explained that her tumour would be removed, genetically analysed, and used to create a personalised vaccine designed to help her immune cells recognise the mutations found only in her cancer.
Donna went on to receive an immunotherapy drug, eight vaccine doses, chemotherapy and then a final vaccine dose. Today, she is 72. She and Ed celebrated their 50th wedding anniversary in Sicily last year, and they continue to travel and spend time with their three daughters and six grandchildren.
For researchers, stories like Donna’s are not just inspiring. They also raise a powerful scientific question: why do some patients live longer than expected, and can their immune response be understood, replicated and strengthened for others?
Why Pancreatic Cancer Needs New Approaches
Pancreatic cancer is the third leading cause of cancer-related death in the United States and is expected to rise to the second leading cause in the coming years. Even when tumours can be surgically removed, the disease often returns.
Standard treatments, including chemotherapy, radiation, targeted therapy and current immunotherapies, have had limited impact for many patients. This is why therapeutic cancer vaccines have become such an important area of research.
However, developing cancer vaccines is especially difficult. Cancer cells come from the patient’s own body, which makes them harder for the immune system to distinguish from normal cells. A successful vaccine must identify the right tumour targets and generate a strong enough immune response to keep fighting over time.
That challenge becomes even greater in cancers like pancreatic cancer, where many existing immunotherapy approaches have struggled.
Phase 2 Trial Now Underway
Based on the phase 1 findings, a global phase 2 clinical trial sponsored by Genentech in collaboration with BioNTech is now testing autogene cevumeran in a larger patient population. The study is taking place at MSK and other sites around the world.
This next phase will be crucial. The phase 1 results are encouraging, but a larger trial is needed to understand whether the vaccine can deliver consistent clinical benefits across a broader group of patients.
The pancreatic cancer research community appears to be increasingly focused on the possibility that the patient’s own immune system could become a more powerful weapon against the disease, provided it can be trained with enough precision.
MSK Expands mRNA Vaccine Manufacturing Ambitions
The research is also prompting wider questions about access and production. At present, many personalised cancer vaccines remain restricted to clinical trials run by pharmaceutical companies and offered at a limited number of hospitals.
MSK is now working to expand its own capability through the Olayan Center for Cancer Vaccines. The centre is establishing mRNA vaccine manufacturing infrastructure in Manhattan, with the aim of enabling on-site production and delivery of personalised vaccines for patients with a range of cancers.
This could become an important step in moving personalised cancer vaccines from highly specialised research settings towards broader clinical testing.
MSK researchers are also studying a separate ready-made vaccine for patients whose pancreatic cancer is driven by KRAS mutations. The KRAS-targeting vaccine, called ELI-002 2P, has shown in phase 1 testing that it may help some patients live longer without cancer returning. A phase 2 trial, led by Dr O’Reilly and surgical oncologist Kevin C. Soares, MD, is expected to open in 2026.
Unlike fully personalised vaccines, KRAS-targeting vaccines could potentially be mass-produced and stored for faster use.
Impact on Pharmaceutical Manufacturing and Production
The progress around personalised mRNA cancer vaccines could have a major impact on pharmaceutical manufacturing and production.
Traditional drug manufacturing is often built around producing large batches of the same medicine for many patients. Personalised cancer vaccines challenge that model because each vaccine may need to be designed and manufactured for one individual based on their tumour genetics.
That creates new demands across sequencing, data processing, quality control, cold-chain logistics, regulatory oversight and rapid production timelines.
If therapies such as autogene cevumeran continue to advance, pharmaceutical manufacturers may need to invest in more flexible, decentralised and digitally connected production systems.
Hospitals and specialist cancer centres could also become more closely involved in manufacturing, particularly where speed and personalisation are essential. In this sense, the future of pharmaceutical production may not only be about scale, but about precision, speed and the ability to make highly tailored treatments safely and reliably.
Merck Deepens Its AI Strategy with Google Cloud
Away from cancer vaccines, Merck & Co. has announced a major artificial intelligence partnership with Google Cloud, marking another sign of how seriously large pharmaceutical companies are now taking digital transformation.
Merck is making a multiyear investment worth up to $1 billion through the deal. The company plans to apply AI tools across research and development, manufacturing, commercial operations and corporate functions.
The move reflects a broader trend across the pharmaceutical industry, where AI is being used to accelerate drug discovery, improve clinical development, streamline production and strengthen commercial decision-making.
For Merck, the Google Cloud partnership appears to be less about a single project and more about building the digital backbone of an AI-enabled pharmaceutical business.
Merck Wins FDA Approval for Idvynso
Merck has also secured Food and Drug Administration clearance for Idvynso, a new two-drug combination therapy for HIV.
The drug has been approved as a replacement therapy for adults with HIV-1 whose viral levels are already suppressed by another treatment regimen. Idvynso combines Merck’s previously approved medicine Pifeltro with the newer agent islatravir in a single tablet.
The approval follows a complicated development journey, with previous studies halted over safety concerns. However, the drug has now achieved the first of what could become two FDA approvals. A future decision could allow Idvynso to be used in treatment-naive patients as well.
Analysts have suggested that while Idvynso is unlikely to materially disrupt Gilead Sciences’ dominant HIV therapy Biktarvy, Merck’s once-monthly oral preventive therapy may carry greater commercial upside.
Roche Makes Its Case in Multiple Sclerosis
Roche, meanwhile, has presented detailed results for fenebrutinib, an experimental oral therapy for multiple sclerosis.
Data from two studies presented at the American Academy of Neurology meeting showed that, compared with Sanofi’s Aubagio over 96 weeks, fenebrutinib reduced annual relapse rates by 51.1% in one trial and 58.5% in another.
Roche said this performance equates to patients experiencing one relapse every 17 years.
However, the drug’s approval prospects are still under scrutiny. Some analysts have raised concerns around an imbalance in patient deaths in the trials and liver-related side effects, a known regulatory concern for similar medicines.
Roche has stated that rates of liver enzyme spikes were comparable between patients receiving Aubagio and those receiving fenebrutinib.
Arcus and Gilead End a Longstanding Cancer Alliance
In oncology, Arcus Biosciences and Gilead Sciences have halted a phase 3 trial testing two Arcus immunotherapies plus chemotherapy against Merck’s Keytruda plus chemotherapy in non-small cell lung cancer. The trial was stopped for futility.
Arcus also disclosed that the partners are ending a cancer-focused research collaboration that began in 2020.
The decision follows an earlier failure in gastroesophageal cancers and comes as Arcus shifts attention towards other pipeline candidates, including casdatifan, a drug it is advancing for kidney tumours.
While the end of a major alliance can be seen as a setback, some analysts view it as an opportunity for Arcus to pursue broader business development options around its remaining pipeline.
Ray Therapeutics Raises $125 Million for Vision-Restoring Gene Therapies
Ray Therapeutics has also raised a further $125 million to advance gene therapies designed to restore vision in people with blinding eye conditions.
The financing round includes support from investors such as Janus Henderson Investors, Adage Capital Management, Deerfield Management and Novo Holdings.
The funds will support late-stage development of Ray’s lead programme in retinitis pigmentosa, as well as earlier testing for Stargardt disease and geographic atrophy.
Ray is developing optogenetic therapies that deliver light-sensitive proteins into retinal cells. The hope is that this approach could help patients regain sight regardless of the specific genetic mutation causing their disease.
A Pharmaceutical Industry Being Rebuilt Around Precision
Taken together, these developments show a pharmaceutical industry moving in several directions at once, but with one clear connecting thread: precision.
At MSK, BioNTech and Genentech, precision means tailoring an mRNA vaccine to the unique mutations in a patient’s tumour. At Merck, it means using AI to sharpen research, manufacturing and commercial systems. At Roche, it means targeting multiple sclerosis with a new oral therapy. At Ray Therapeutics, it means using gene therapy to address vision loss at the cellular level.
At the same time, the Arcus and Gilead update is a reminder that pharmaceutical innovation remains difficult, expensive and uncertain. Not every trial succeeds, and not every alliance lasts. But the failures also help redirect resources towards the candidates and technologies with the strongest future potential.
Conclusion: A Defining Moment for mRNA, AI and Next-Generation Pharma
The latest pancreatic cancer vaccine results from MSK, BioNTech and Genentech are still early, but they represent one of the more compelling signals in a disease area badly in need of progress. The idea that a patient’s own immune system can be trained to recognise and attack pancreatic cancer over many years is both scientifically ambitious and deeply human.
At the same time, Merck’s $1 billion Google Cloud partnership, its HIV approval, Roche’s multiple sclerosis data, the Gilead and Arcus split, and Ray Therapeutics’ new financing all point to a sector undergoing rapid reinvention.
The pharmaceutical industry is no longer being shaped by drug chemistry alone. It is being reshaped by mRNA platforms, AI infrastructure, genetic analysis, immunology, personalised manufacturing and increasingly sophisticated clinical trial strategies.
For patients, that could mean more targeted therapies, more durable responses and, in some of the hardest diseases, new reasons to believe that survival stories can become more common.
News Credits:
Merck adds to pharma’s AI push; Roche details MS drug results
Vous aimerez peut-être aussi :